WO2012154009A3 - 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 - Google Patents

티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2012154009A3
WO2012154009A3 PCT/KR2012/003722 KR2012003722W WO2012154009A3 WO 2012154009 A3 WO2012154009 A3 WO 2012154009A3 KR 2012003722 W KR2012003722 W KR 2012003722W WO 2012154009 A3 WO2012154009 A3 WO 2012154009A3
Authority
WO
WIPO (PCT)
Prior art keywords
thienopyrimidine derivatives
derivatives
preventing
thienopyrimidine
diabetes
Prior art date
Application number
PCT/KR2012/003722
Other languages
English (en)
French (fr)
Other versions
WO2012154009A2 (ko
Inventor
전문국
안진희
강승규
이규명
이상달
김희연
정원훈
김광록
배명애
송진숙
서지희
강명구
김민혜
Original Assignee
한국화학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원 filed Critical 한국화학연구원
Publication of WO2012154009A2 publication Critical patent/WO2012154009A2/ko
Publication of WO2012154009A3 publication Critical patent/WO2012154009A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 신규한 티에노피리미딘 유도체 및 이를 유효성분으로 포함하는 당뇨병 및 다양한 당뇨 관련 질환의 예방 또는 치료용 약제학적 조성물에 관한 것이다. 본 발명의 티에노피리미딘 유도체는 당-의존적 인슐린 분비를 증가시키고 섭식과 체중 증가의 억제효과가 있는 GPR119(G protein-coupled receptor 119)의 활성을 효율적으로 항진시킴으로써 당 및 지질 대사를 개선시켜， 당뇨 뿐 아니라， 비만， 고지혈증， 당뇨병성 혈관질환 등 다양한 당뇨병성 합병증에 대한 효율적인 예방 및 치료용 조성물로 유용하게 이용될 수 있다.
PCT/KR2012/003722 2011-05-12 2012-05-11 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 WO2012154009A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110044605 2011-05-12
KR10-2011-0044605 2011-05-12
KR10-2012-0050290 2012-05-11
KR1020120050290A KR101401496B1 (ko) 2011-05-12 2012-05-11 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2012154009A2 WO2012154009A2 (ko) 2012-11-15
WO2012154009A3 true WO2012154009A3 (ko) 2013-03-21

Family

ID=47139836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003722 WO2012154009A2 (ko) 2011-05-12 2012-05-11 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물

Country Status (2)

Country Link
KR (1) KR101401496B1 (ko)
WO (1) WO2012154009A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR101665846B1 (ko) * 2014-01-23 2016-10-12 동국대학교 산학협력단 Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070057970A (ko) * 2004-09-23 2007-06-07 에픽스 델라웨어, 인코포레이티드 피페리디닐아미노-티에노[2,3-ｄ]피리미딘 화합물
US20090111835A1 (en) * 2004-01-06 2009-04-30 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
KR20090047391A (ko) * 2006-04-07 2009-05-12 데벨로겐 악틴게젤샤프트 약제학적 조성물을 위한 Ｍｎｋ1/Ｍｎｋ2 억제 활성을 갖는티에노피리미딘
KR20110044053A (ko) * 2009-10-22 2011-04-28 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-ｄ]피리미딘 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111835A1 (en) * 2004-01-06 2009-04-30 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
KR20070057970A (ko) * 2004-09-23 2007-06-07 에픽스 델라웨어, 인코포레이티드 피페리디닐아미노-티에노[2,3-ｄ]피리미딘 화합물
KR20090047391A (ko) * 2006-04-07 2009-05-12 데벨로겐 악틴게젤샤프트 약제학적 조성물을 위한 Ｍｎｋ1/Ｍｎｋ2 억제 활성을 갖는티에노피리미딘
KR20110044053A (ko) * 2009-10-22 2011-04-28 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-ｄ]피리미딘 화합물

Also Published As

Publication number Publication date
KR101401496B1 (ko) 2014-06-11
WO2012154009A2 (ko) 2012-11-15
KR20120127309A (ko) 2012-11-21

Similar Documents

Publication Publication Date Title
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MY181539A (en) Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
WO2011107750A3 (en) Delayed prolonged drug delivery
BR112015010314A8 (pt) Composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica, secretagogo de insulina ou agente hipoglicêmico, e, agonista do receptor gpr40
WO2011107755A3 (en) Immediate/delayed drug delivery
EP2727605A4 (en) ANALOGUE OF POLYETHYLENE GLYCOL EXENDIN-4 OR A DERIVATIVE THEREOF, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING THE SAME AS ACTIVE INGREDIENT
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
NZ599848A (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2012154009A3 (ko) 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물
WO2011126342A3 (ko) 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도
WO2012161622A3 (ru) Стимуляторы секреции инкретиновых гормонов, способ их получения и применения
WO2011128910A3 (en) A drug delivery solid dosage formulation of sirolimus
WO2011090265A3 (ko) 신코닌을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12782808

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12782808

Country of ref document: EP

Kind code of ref document: A2